These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29886544)

  • 1. Live Imaging of Pathological Tau Protein and Tau Antibodies in a Neuron-Like Cellular Model.
    Shamir DB; Deng Y; Sigurdsson EM
    Methods Mol Biol; 2018; 1779():371-379. PubMed ID: 29886544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy.
    Congdon EE; Chukwu JE; Shamir DB; Deng J; Ujla D; Sait HBR; Neubert TA; Kong XP; Sigurdsson EM
    EBioMedicine; 2019 Apr; 42():157-173. PubMed ID: 30910484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
    Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
    Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging.
    Wu Q; Lin Y; Gu J; Sigurdsson EM
    EBioMedicine; 2018 Sep; 35():270-278. PubMed ID: 30146345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.
    Agadjanyan MG; Zagorski K; Petrushina I; Davtyan H; Kazarian K; Antonenko M; Davis J; Bon C; Blurton-Jones M; Cribbs DH; Ghochikyan A
    Mol Neurodegener; 2017 May; 12(1):33. PubMed ID: 28472993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
    Combs B; Hamel C; Kanaan NM
    Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of Internalization and Intracellular Interaction of Tau Antibodies and Human Pathological Tau Protein in a Human Neuron-Like Model.
    Shamir DB; Deng Y; Wu Q; Modak S; Congdon EE; Sigurdsson EM
    Front Neurol; 2020; 11():602292. PubMed ID: 33324339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.
    Congdon EE; Jiang Y; Sigurdsson EM
    Semin Cell Dev Biol; 2022 Jun; 126():125-137. PubMed ID: 34896021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
    Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
    J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
    Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.
    West T; Hu Y; Verghese PB; Bateman RJ; Braunstein JB; Fogelman I; Budur K; Florian H; Mendonca N; Holtzman DM
    J Prev Alzheimers Dis; 2017; 4(4):236-241. PubMed ID: 29181488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau Immunotherapy.
    Sigurdsson EM
    Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
    Zhao K; Ippolito G; Wang L; Price V; Kim MH; Cornwell G; Fulenchek S; Breen GA; Goux WJ; D'Mello SR
    J Neurosci Res; 2010 Nov; 88(15):3399-413. PubMed ID: 20882568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain.
    Narasimhan S; Guo JL; Changolkar L; Stieber A; McBride JD; Silva LV; He Z; Zhang B; Gathagan RJ; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Nov; 37(47):11406-11423. PubMed ID: 29054878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
    Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
    Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody.
    Van Kolen K; Malia TJ; Theunis C; Nanjunda R; Teplyakov A; Ernst R; Wu SJ; Luo J; Borgers M; Vandermeeren M; Bottelbergs A; Wintmolders C; Lacy E; Maurin H; Larsen P; Willems R; Van De Casteele T; Triana-Baltzer G; Slemmon R; Galpern W; Trojanowski JQ; Sun H; Mercken MH
    J Alzheimers Dis; 2020; 77(4):1397-1416. PubMed ID: 32894244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity.
    Congdon EE; Pan R; Jiang Y; Sandusky-Beltran LA; Dodge A; Lin Y; Liu M; Kuo MH; Kong XP; Sigurdsson EM
    EBioMedicine; 2022 Oct; 84():104249. PubMed ID: 36099813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia.
    De Marco D; Taggenbrock R; Crespo R; Koudstaal W; Ramsburg E; Apetri A
    J Vis Exp; 2018 Nov; (141):. PubMed ID: 30474638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.